医学
唑来膦酸
颌骨骨坏死
多发性骨髓瘤
入射(几何)
外科
置信区间
B组
并发症
内科学
双膦酸盐
骨质疏松症
光学
物理
作者
Meletios Α. Dimopoulos,Efstathios Kastritis,Christina Bamia,Ioannis Melakopoulos,Dimitra Gika,Μαρία Ρούσσου,Magdalini Migkou,Evangelos Eleftherakis-Papaiakovou,Dimitrios Christoulas,Evangelos Terpos,Aristotle Bamias
标识
DOI:10.1093/annonc/mdn554
摘要
Osteonecrosis of the jaw (ONJ) is a well-described complication of bisphosphonates use in patients with multiple myeloma (MM). We investigated whether the occurrence of ONJ decreased after the implementation of preventive measures in 128 patients with MM who received zoledronic acid.Patients with MM who received zoledronic acid were included in this analysis. Patients with a previous use of other bisphosphonates were excluded; patients were stratified into group A (n=38) and group B (n=90) if treatment was started before or after the implementation of preventive measures.One hundred and twenty-eight patients were included in this analysis. Sixteen patients (12.5%) developed ONJ--group A: 8 (26.3%), group B: 2 (6.7%) (P=0.002). The incidence rate (IR) was 0.671/100 person-months for group A and 0.230/100 person-months for group B [IR ratio 2.92, P=0.029, 95% confidence interval 1.06-8.03]. No patient in group B developed stage III ONJ.In conclusion, the risk of developing ONJ after treatment of zoledronic acid is reduced (but not deleted) by the implementation of preventive measures.
科研通智能强力驱动
Strongly Powered by AbleSci AI